#1 Clinical Trials Search in Europe

Tacrolimus

This article explores clinical trials investigating different formulations of tacrolimus, an important immunosuppressant drug used to prevent organ rejection in transplant patients. The studies compare extended-release versions like Envarsus XR and Astagraf XL to standard immediate-release tacrolimus (Prograf) in terms of efficacy, safety, and patient outcomes. Researchers are examining how these formulations affect drug absorption, dosing requirements, side effects, and medication adherence in various transplant populations.

Table of Contents

What is Tacrolimus?

Tacrolimus is a powerful immunosuppressant medication used to prevent organ rejection in transplant patients and treat certain autoimmune conditions. It’s also known by the brand names Prograf, Advagraf, and FK506[1]. Tacrolimus works by suppressing the body’s immune system to prevent it from attacking transplanted organs or healthy tissues in autoimmune diseases.

Uses of Tacrolimus

Tacrolimus is primarily used in the following medical situations:

  • Organ Transplantation: It’s commonly used to prevent rejection after kidney, liver, and other organ transplants[2][3].
  • Graft-versus-Host Disease (GVHD): Tacrolimus helps prevent and treat GVHD in patients who have received stem cell transplants[4].
  • Autoimmune Conditions: It’s used to treat certain autoimmune diseases like atopic dermatitis (a type of eczema) and membranous nephropathy (a kidney disorder)[5][6].

How Tacrolimus Works

Tacrolimus works by suppressing the activity of T-cells, which are a type of white blood cell responsible for immune responses. Specifically, it:

  • Inhibits the production of certain proteins (cytokines) that activate T-cells
  • Reduces the ability of T-cells to recognize and attack foreign substances (like transplanted organs) or the body’s own tissues (in autoimmune diseases)

By dampening the immune response, tacrolimus helps prevent organ rejection and reduces inflammation in autoimmune conditions[6].

Forms and Administration of Tacrolimus

Tacrolimus comes in several forms:

  • Oral capsules: Taken twice daily (e.g., Prograf) or once daily (e.g., Envarsus XR, Astagraf XL)[1]
  • Topical ointment: Applied to the skin for conditions like atopic dermatitis[5]
  • Injectable form: Used in hospital settings

The dosage and frequency of tacrolimus administration depend on the specific condition being treated, the patient’s response, and other factors. It’s crucial to take tacrolimus exactly as prescribed by your doctor.

Tacrolimus in Clinical Trials

Tacrolimus is being studied in various clinical trials to optimize its use and explore new applications. Some areas of research include:

  • Comparing different formulations of tacrolimus for better efficacy and fewer side effects[1]
  • Using tacrolimus in combination with other medications to improve outcomes in organ transplantation[2][3]
  • Exploring the use of tacrolimus in treating autoimmune conditions like membranous nephropathy[6]
  • Investigating tacrolimus as part of immunosuppression regimens in stem cell transplantation[4]

Potential Side Effects

Like all medications, tacrolimus can cause side effects. Some potential side effects include:

  • Increased risk of infections due to suppressed immune system
  • Kidney problems
  • High blood pressure
  • Diabetes
  • Tremors
  • Headache
  • Gastrointestinal issues (nausea, diarrhea)

When used as a topical ointment for skin conditions, tacrolimus may cause temporary burning or itching at the application site[5].

Monitoring During Tacrolimus Treatment

Patients taking tacrolimus require regular monitoring to ensure the medication is working effectively and to catch any potential side effects early. This monitoring typically includes:

  • Blood tests: To check tacrolimus levels in the blood and monitor kidney and liver function
  • Blood pressure checks
  • Blood sugar tests: To watch for the development of diabetes
  • Regular check-ups: To assess overall health and any potential side effects

Your healthcare provider will adjust your tacrolimus dose based on these monitoring results to achieve the best balance between effectiveness and minimizing side effects[2].

Aspect Details
Study Objectives Compare pharmacokinetics, efficacy, safety, and patient outcomes between extended-release (Envarsus XR, Astagraf XL) and immediate-release (Prograf) tacrolimus formulations
Patient Populations Kidney, liver, and simultaneous pancreas-kidney transplant recipients; some studies focus on adolescents or patients who have undergone sleeve gastrectomy
Key Measurements Drug absorption (AUC, Cmax, Tmax), kidney function (eGFR, creatinine), rejection markers (donor-specific antibodies, biopsies), patient-reported outcomes (quality of life, side effects, medication adherence)
Potential Benefits of Extended-Release Formulations Improved medication adherence, reduced side effects, more consistent drug levels, simplified dosing regimen
Study Designs Randomized crossover trials, pharmacokinetic comparisons, prospective single-arm studies

FAQ

  • What is tacrolimus and why is it used in transplant patients? Tacrolimus is an immunosuppressant medication used to prevent organ rejection in transplant recipients. It works by suppressing the immune system to stop it from attacking the transplanted organ.
  • What are the different formulations of tacrolimus being studied? The main formulations being compared are extended-release versions like Envarsus XR and Astagraf XL (taken once daily) and the standard immediate-release tacrolimus (Prograf, taken twice daily).
  • What are researchers trying to determine about these different formulations? Researchers are examining how the formulations compare in terms of drug absorption and concentration in the blood, dosing requirements, efficacy in preventing rejection, side effects, and how well patients adhere to taking the medication as prescribed.
  • What types of transplant patients are being included in these studies? The studies include kidney transplant recipients, simultaneous pancreas-kidney transplant recipients, and liver transplant recipients. Some focus specifically on adolescent kidney transplant patients.
  • How might extended-release formulations benefit patients? Extended-release formulations taken once daily may improve medication adherence, reduce side effects, and provide more consistent drug levels in the blood compared to twice-daily immediate-release tacrolimus.

Ongoing Clinical Trials on Tacrolimus

  • AUC‑targeted tacrolimus dosing in kidney transplant recipients

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Norway

  • Study of Melpida with drug combination in patients with Hereditary Spastic Paraplegia Type 50 (SPG50)

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    Spain

  • Tacrolimus for prevention of post-ERCP pancreatitis in moderate- to high-risk patients

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    The Netherlands

  • Study on the Safety and Effectiveness of Tacrolimus and Drug Combination for Patients with BK Polyomavirus Infection After Kidney Transplantation

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    Germany

  • Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    Austria Czechia Denmark France Germany Hungary +7

  • Study of anakinra and a drug combination to prevent blood clots in patients receiving a pancreatic transplant

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France

  • Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    Austria Belgium Czechia Finland France Germany +7

  • Comparing tacrolimus and mycophenolate mofetil bioequivalence in kidney transplant recipients taking immunosuppressive medications

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Norway

  • Study on Reducing Tacrolimus Dose in Kidney Transplant Patients Using LCPT Compared to Tacrolimus-ER

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands

  • Study on Long-Term Safety of Tegoprubart and Tacrolimus for Preventing Kidney Transplant Rejection in Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Spain

Glossary

  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized and eliminated by the body over time. This helps determine proper dosing.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, calculated from blood concentration measurements. Higher AUC generally means more drug absorption.
  • Tmax: The time it takes to reach the maximum concentration of a drug in the blood after taking a dose.
  • Cmax: The peak or maximum concentration of a drug reached in the blood after taking a dose.
  • eGFR: Estimated glomerular filtration rate – a measure of kidney function based on blood tests.
  • Donor-specific antibodies (DSA): Antibodies produced by a transplant recipient that react specifically against the donor's tissues. These can indicate rejection.
  • Biopsy-proven rejection: Rejection of a transplanted organ that is confirmed through examination of a tissue sample under a microscope.
  • Laparoscopic sleeve gastrectomy: A weight loss surgery that removes a large portion of the stomach, potentially affecting drug absorption.

References

  1. https://clinicaltrials.gov/study/NCT02339246
  2. https://clinicaltrials.gov/study/NCT06235892
  3. https://clinicaltrials.gov/study/NCT00321074
  4. https://clinicaltrials.gov/study/NCT02178683
  5. https://clinicaltrials.gov/study/NCT03645057
  6. https://clinicaltrials.gov/study/NCT01955187